Acquisition

Sai Parenterals to buy control of Bion, targets November 30 close

What's the deal? Sai ParenteralsDealroom has a profile for this one. Try Dealroom → approved an all-cash acquisition of a majority stake in Bion Therapeutics (India) through its subsidiary SP Analytics, with completion targeted by November 30, 2026. The board signed off at its November 16 meeting. Bion is a Hyderabad-based branded prescription formulations business.

The terms: The deal value is undisclosed. The filing does not state the exact stake, the selling shareholders, or the rupee consideration, saying the price will rest on a valuation by an independent valuer. Bion would become a step-down subsidiary of Sai Parenterals once the deal closes.

How it's funded: Sai Parenterals plans to back SP Analytics using initial public offering proceeds earmarked for general corporate purposes, plus debt. The company says no governmental or regulatory approvals are needed for the transaction.

The numbers: Bion reported total income of US$6.42M in 2025-26, up US$20.4K from US$6.4M the prior year. For the half-year ended September 30, 2026, it posted US$3.9M in total income — roughly 61% of the preceding full year. The filing offers no profit, net worth, or margin data.

Why now? The move follows a string of acquisitions by Sai Parenterals. It recently took 60% of Prathyak Laboratories for US$2.04M, adding an R&D facility in Hyderabad, and agreed to buy out the remaining 25% of SP Analytics to make it wholly owned by December 31, 2026.

The signal: The deal fits a wider pattern of Indian pharma M&A aimed at bolting on manufacturing and formulation capabilities. But with the stake, valuation, and consideration all undisclosed, its strategic weight for Sai Parenterals remains hard to judge.

Read more: multibagg.ai

Image credit: Generated with Gemini

More top stories